Bezisterim has been approved as the non-proprietary name for NE3107Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation ...
CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (BioVie or the Company), a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
Even after raising $21 million in equity last week, BioVie is still axing the biotech’s “most de-risked program,” a phase 3-ready investigational infusion for patients with refractory ascites, a common complication of liver cirrhosis.
BioVie Inc. Announces Closing of Public Offering
BioVie Inc. Announces Pricing of Public Offering
BioVie™s NE3107 Demonstrates Improvements in Motor and Non-motor Symptoms
BioVie Inc. Announces Proposed Public Offering of Common Stock
CARSON CITY, Nev., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (BioVie or the Company) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie blames trial site exclusions for failed Alzheimer`s drug study